Human iPSC sourcing & reprogramming

Ncardia assists clients in securing iPSC lines from healthy and patient donors. Integrated into the Platform is access to a menu of sourcing options including access to Ncardia’s in-house, qualified healthy and disease hiPSC lines or sourcing of healthy and disease hiPSC lines through established relationships with leading medical centers and consortiums

Contact us
Ncardia scientists talking in the lab

iPSC Sourcing

Upon request, we establish the required characteristics of the iPSC with the client. Ncardia then idenitifies applicable hiPSC lines based on age, gender and reprogramming technology with matched controls. Ncardia has a menu of qualified induced pluripotent stem cell lines that we routinely utilize in commercial products, innovation developments and in the service of client projects. We also have established relationships with 3rd party partners, including leading hospitals and consortiums, from which we routinely source healthy and patient hiPSC lines.

All iPSC lines undergo standard quality control including sterility, mycoplasma testing, pluripotency analysis by FACS, and genome integrity by digital PCR and STR analysis. Relevant documentation and medical ethical approvals for derivation of iPSC lines are confirmed and secured by Ncardia.

Close-up plating of hiPSC-derived cells

iPSC Reprogramming Service

Our stem cell experts reprogram human primary cells from fibroblasts, PBMC or CD34+ cells to generate pluripotent stem cells. All primary cells are obtained under an IRB-approved ethical consent procedure. Human iPSCs are authenticated by DNA fingerprinting (STR analysis) of the parental somatic cells and the respective hiPSC clones.

We utilize non-integrating technologies to efficiently generate iPSCs, frequently Sendai or episomal reprogramming. Reprogramming projects are typically completed within 12 to 18 weeks. Project-specific timelines will depend on the cell type provided, choice of reprogramming technology, and any additional optional characterization or assays requested.

Generally, two to four clones are cryopreserved per donor. Clones are tested for mycoplasma and a panel of human pathogens. Expression of stem cell markers, spontaneous differentiation and IF staining of mesoderm, ectoderm and endoderm are assayed. Genomic integrity with regard to common abnormalities is evaluated by digital PCR.

Ncardia scientists in the lab, looking at computer

The Ncardia iPSC Platform for Drug Discovery and Cell Therapy

Building better cell models and assays at scale to make the implementation of stem cell technology in Drug Discovery and Cell Therapy possible.


Contact us